Streetbeat News

Revenues

VERI

Veritone forecasts its Q1 revenue to be between $30.5M and $31.5M, slightly below the estimated $31.42M. For FY24, the company expects revenue to range from $134M to $142M, which is around the $135.83M estimate.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:46 pm

ARGT

VINO

Argentine stocks, particularly the Global X MSCI Argentine ETF (ARGT), experienced a surge following the central bank's decision to cut interest rates by 20 percentage points to 80%, in response to lower-than-expected February inflation figures. The government attributes the inflation slowdown to its fiscal discipline. Additionally, President Milei is considering the inclusion of the U.S. dollar as legal tender to combat inflation further. Gaucho Group Holdings (VINO) is also mentioned in the context of Argentina's potential dollarization.

Portfolio Pulse from Piero Cingari

March 12, 2024 | 8:46 pm

NATR

Nature's Sunshine projects its full year 2024 net sales to be between $455M and $480M, with an estimated average of $464.277M. The company also forecasts its adjusted EBITDA for the same period to be in the range of $42M to $48M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:45 pm

INVE

Identiv forecasts Q1'2024 net revenues to be between $22M-$24M, below the estimated $26.767M. The company anticipates normal seasonality to continue.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:43 pm

CLOV

Clover Health Investments Corp (NASDAQ:CLOV) reported Q4 sales of $510.3 million, surpassing analyst estimates and marking a significant improvement in Adjusted EBITDA. The company anticipates 2024 insurance revenue between $1.25 billion and $1.3 billion, reflecting confidence in its business model and future prospects. Shares rallied after-hours following the announcement.

Portfolio Pulse from Erica Kollmann

March 12, 2024 | 8:43 pm

LSF

Laird Superfood (AMEX:LSF) reported Q4 sales of $9.200M, surpassing the analyst consensus estimate of $8.736M by 5.31% and marking a 2.56% increase over the previous year's sales of $8.970M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:40 pm

AIRE

reAlpha Tech Corp. reported financial results for the 8-month transition period ending December 31, 2023, with an EPS of $(0.03), improved from $(0.13) the previous year. Revenue decreased to $121,690 from $284,666, mainly due to lower rental income and the sale of myAlphie. Cash and equivalents rose to $6,456,370 from $1,256,868. Net loss decreased to $1,251,259 from $4,241,555, largely due to the sale of myAlphie. Adjusted EBITDA improved to $(2,297,480) from $(4,031,674).

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:37 pm

HRTX

Heron Therapeutics has reaffirmed its financial guidance for FY24, projecting net product revenues between $138M-$158M, adjusted operating expenses between $108M-$116M, and adjusted EBITDA ranging from a loss of $22M to a gain of $3M, excluding stock-based compensation and depreciation and amortization.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:30 pm

SIGA

SIGA Technologies reported total revenues of $116.5 million for the three months ended December 31.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:28 pm

LYV

SSSS

Liquid Death, a rapidly growing beverage company, announced a new funding round of $67 million, reaching a valuation of $1.4 billion. The company, known for its canned water, flavored sparkling water, and iced tea, has attracted new investors including SuRo Capital (NASDAQ:SSSS) and Live Nation Entertainment (NYSE:LYV), along with celebrity investors like Josh Brolin and DeAndre Hopkins. The funding will support product innovation and operational scaling. Liquid Death reported $263 million in retail sales in 2023 and has expanded to 113,000 retail locations in the US and UK.

Portfolio Pulse from Chris Katje

March 12, 2024 | 8:27 pm